BioCentury
ARTICLE | Clinical News

Eprodisate: Development discontinued

May 10, 2010 7:00 AM UTC

Bellus discontinued its NC-503 diabetes development program after the compound missed the primary endpoint in a Phase IIa trial to treat Type II diabetes. The compound is also in Phase III testing as ...